New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (Obinutuzumab) for Primary Membranous Nephropathy (pMN). Click here for more information. Please visit our Patient Navigation tool for support.

RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Lindsey Duquette

Coordinator, Corporate Partnerships

Lindsey serves as NephCure’s Corporate Partnerships Coordinator and holds a bachelor's degree in political science from Loyola University Maryland. A rare kidney disease patient herself, Lindsey was diagnosed with Nephrotic Syndrome when she was two years old. The disease was later discovered to be Focal Segmental Glomerulosclerosis (FSGS). As a result of lack of treatment options, Lindsey experienced 172 hospitalizations and 22 surgeries over the course of 8 years in a failed effort to save her native kidneys. Lindsey experienced peritoneal and hemodialysis, has been on countless combinations of medications (including prednisone, rituximab, and Cytoxan), and received a living donor kidney transplant in June 2012. Post-transplant life has been transformative, allowing her to pursue her passions of painting, playing several musical instruments, and video games.

Lindsey understands first-hand the journey of a rare disease patient and has dedicated herself to advocating for better healthcare and treatment options for all kidney patients.

Washington, D.C.

Related News

NEWS

The FDA Grants Accelerated Approval of ULTOMIRIS (ravulizumab-cwvz) for Adults with IgA Nephropathy 

NEWS

NephCure Applauds U.S. Department of Health and Human Services on the Release of the Rare Kidney Disease Inclusive Kidney Care National Plan

NEWS

NephCure Celebrates C3G Awareness Day on September 25, 2026

NEWS

NephCure Specialist of the Month: Dr. Rupali Avasare

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.